Payers: Commercial

UnitedHealth-Mayo: More Data, More Open. But Not Quite Neutral

Posted on Jan 22, 2013 in Affordable Care Act, Cost/Comparative Effectiveness, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Physician practice patterns, Pricing

UnitedHealth’s outcomes-focused research alliance with Mayo Clinic, announced Jan. 15, reminds us of big data’s central role in creating a value-driven US health care system.  The tie-up claims to have...

Learn More

Reimbursement “Furies” Real, But Won’t Avenge Pharma Til 2017, Says Citi

Posted on Dec 4, 2012 in Adherence, Company, Cost/Comparative Effectiveness, Diagnostics, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Pricing

“Beware the Three Furies,” warns Citi analyst Andrew Baum.  In a report for pharma investors published Nov. 29., Baum turns to classical mythology to describe shared savings models, drug pathways...

Learn More

Sanofi Blinks First: Zaltrap Price Cut Proves HTA Has Reached The US

Posted on Nov 12, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Pricing, Product Launch, Value-based pricing

Sanofi’s decision last week to cut the price of its colon cancer drug Zaltrap by up to 50% showed that the US market is no longer immune to European-style drug price pressure. Never mind that the move...

Learn More

Actelion’s Opsumit Will Test Whether Outcomes Data Can Replace Head-to-Head

Posted on Nov 2, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payers: Commercial, Payers: Managed Medicaid/Medicare, Pharmaceuticals, Pricing, Product Launch

Actelion pulled out all the stops in designing the Phase III trial of its pulmonary arterial hypertension drug Opsumit (macitentan), filed at FDA on Oct 22.  And no wonder: the biotech’s future depends on it,...

Learn More